文献速递妇科肿瘤

宫颈癌开腹与微创根治性子宫切除术后生活质量:LACC试验次要结局

Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial.
PubMed 文献 · Lancet Oncol · 2020-01-01

LACC试验是一项多中心随机开放标签3期非劣效试验,比较早期宫颈癌开腹与微创根治性子宫切除术。结合微创手术无病生存更差,作者建议早期宫颈癌推荐开腹根治性子宫切除术。

要点

  • 早期宫颈癌微创根治性子宫切除术后生活质量与开腹手术相似。
  • 微创手术无病生存更差且复发率更高,即使生活质量相当。
  • 妇科肿瘤医生应推荐开腹根治性子宫切除术作为早期宫颈癌标准。

核心结论

  • 早期宫颈癌患者中,微创根治性子宫切除术后生活质量与开腹手术相似,但微创手术无病生存更差且复发率更高,故应推荐开腹手术。

研究设计与样本

  • LACC试验为多中心随机开放标签3期非劣效试验,纳入631例早期宫颈癌患者,随机1:1接受开腹或微创根治性子宫切除术。
  • 生活质量分析纳入496例完成至少一次基线和一次随访问卷的患者,采用广义估计方程比较组间差异。

临床怎么用

  • 对于早期宫颈癌(FIGO IA1伴淋巴血管间隙浸润、IA2或IB1),应推荐开腹根治性子宫切除术而非微创手术。
  • 生活质量相似不应作为选择微创手术的理由,因微创手术肿瘤学结局更差。

局限性

  • 生活质量为次要终点,分析人群为改良意向治疗人群,仅79%随机患者纳入。
  • 开放标签设计可能影响患者报告结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the phase 3 LACC trial and a subsequent population-level review, minimally invasive radical hysterectomy was shown to be associated with worse disease-free survival and higher recurrence rates than was open radical hysterectomy in patients with early stage cervical cancer. Here, we report the results of a secondary endpoint, quality of life, of the LACC trial. METHODS: The LACC trial was a randomised, open-label, phase 3, non-inferiority trial done in 33 centres worldwide. Eligible participants were women aged 18 years or older with International Federation of Gynaecology and Obstetrics (FIGO) stage IA1 with lymphovascular space invasion, IA2, or IB1 adenocarcinoma, squamous cell carcinoma, or adenosquamous carcinoma of the cervix, with an Eastern Cooperative Oncology Group performance status of 0 or 1, who were scheduled to have a type 2 or 3 radical hysterectomy. Participants were randomly assigned (1:1) to receive open or minimally invasive radical hysterectomy. Randomisation was done centrally using a computerised minimisation program, stratified by centre, disease stage according to FIGO guidelines, and age. Neither participants nor investigators were masked to treatment allocation. The primary endpoint of the LACC trial was disease-free survival at 4·5 years, and quality of life was a secondary endpoint. Eligible patients completed validated quality-of-life and symptom assessments (12-item Short Form Health Survey [SF-12], Functional Assessment of Cancer Therapy-Cervical [FACT-Cx], EuroQoL-5D [EQ-5D], and MD Anderson Symptom Inventory [MDASI]) before surgery and at 1 and 6 weeks and 3 and 6 months after surgery (FACT-Cx was also completed at additional timepoints up to 54 months after surgery). Differences in quality of life over time between treatment groups were assessed in the modified intention-to-treat population, which included all patients who had surgery and completed at least one baseline (pretreatment) and one follow-up (at any timepoint after surgery) questionnaire, using generalised estimating equations. The LACC trial is registered with ClinicalTrials.gov, NCT00614211. FINDINGS: Between Jan 31, 2008, and June 22, 2017, 631 patients were enrolled; 312 assigned to the open surgery group and 319 assigned to the minimally invasive surgery group. 496 (79%) of 631 patients had surgery completed at least one baseline and one follow-up quality-of-life survey and were included in the modified intention-to-treat analysis (244 [78%] of 312 patients in the open surgery group and 252 [79%] of 319 participants in the minimally invasive surgery group). Median follow-up was 3·0 years (IQR 1·7-4·5). At baseline, no differences in the mean FACT-Cx total score were identified between the open surgery (129·3 [SD 18·8]) and minimally invasive surgery groups (129·8 [19·8]). No differences in mean FACT-Cx total scores were identified between the groups 6 weeks after surgery (128·7 [SD 19·9] in the open surgery group vs 130·0 [19·8] in the minimally invasive surgery group) or 3 months after surgery (132·0 [21·7] vs 133·0 [22·1]). INTERPRETATION: Since recurrence rates are higher and disease-free survival is lower for minimally invasive radical hysterectomy than for open surgery, and postoperative quality of life is similar between the treatment groups, gynaecological oncologists should recommend open radical hysterectomy for patients with early stage cervical cancer. FUNDING: MD Anderson Cancer Center and Medtronic.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Frumovitz M, Obermair A, Coleman RL, et al. Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2020. PMID: 32502445. doi:10.1016/S1470-2045(20)30081-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。